Press release
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from
About this update from Regeneron Pharmaceuticals, Inc.
[{"type":"text","content":"New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosing\nTARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026. These include new clinical data supporting the efficacy and safety of EYLEA HD® (aflibercept) Injection 8 mg for treating patients with serious retinal diseases. “New presentations will further highlight the EYLEA HD clinical profile, showcasing its unparalleled durability, while allowing similar efficacy and safety to EYLEA 2 mg, but with fewer injections. This includes the Phase 3 data supporting EYLEA HD approval in RVO, where its durability offers the first every-two-month treatment option in the setting, prior to which monthly treatment was required with all other anti-VEGF agents,” said Boaz Hirshberg, M.D., Senior Vice President, Clinical Development, Internal Medicine at Regeneron. “In addition, while EYLEA HD allows for most patients to achieve longer dosing intervals, data will also be presented from the ELARA trial, supporting EYLEA HD approval as a monthly treatment for the small number of patients who need more frequent treatment. Presentations will show that patients who switched to monthly EYLEA HD from other anti-VEGF agents generally improved their vision, while also achieving better anatomic control.” EYLEA HD was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with macular edema following retinal vein occlusion (RVO) based on data from the Phase 3 QUASAR trial, which met its primary endpoint at 36 weeks, and provides the first every-two-month treatment option for these patients who previously required more frequent treatment. At Angiogenesis, final, long-term results through the end of the trial (at 64 weeks) will be presented for the first time. Angiogenesis will also mark the first presentation of full primary data from ELARA, a single-arm, Phase 3b trial evaluating EYLEA HD dosed every 4 weeks in previously treated patients with wet age-related macular degen...